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Effect of Blood Pressure Control on Long-Term Risk of End-Stage
Renal Disease and Death Among Subgroups of Patients With
Chronic Kidney Disease
Elaine Ku, MD, MAS; Mark J. Sarnak, MD; Robert Toto, MD; Charles E. McCulloch, PhD; Feng Lin, MS; Miroslaw Smogorzewski, MD;
Chi-yuan Hsu, MD, MSc
Background-—Our objective was to explore the effect of intensive blood pressure (BP) control on kidney and death outcomes
among subgroups of patients with chronic kidney disease divided by baseline proteinuria, glomerular filtration rate, age, and body
mass index.
Methods and Results-—We included 840 MDRD (Modification of Diet in Renal Disease) trial and 1067 AASK (African American
Study of Kidney Disease and Hypertension) participants. We used Cox models to examine whether the association between
intensive BP control and risk of end-stage renal disease (ESRD) or death is modified by baseline proteinuria (≥0.44 versus
<0.44 g/g), glomerular filtration rate (≥30 versus <30 mL/min per 1.73 m2), age (≥40 versus <40 years), or body mass index
(≥30 versus <30 kg/m2). The median follow-up was 14.9 years. Strict (versus usual) BP control was protective against ESRD
(hazard ratio [HR]ESRD, 0.77; 95% CI, 0.64–0.92) among those with proteinuria ≥0.44 g/g but not proteinuria <0.44 g/g. Strict
(versus usual) BP control was protective against death (HRdeath, 0.73; 95% CI, 0.59–0.92) among those with glomerular filtration
rate <30 mL/min per 1.73 m2 but not glomerular filtration rate ≥30 mL/min per 1.73 m2 (HRdeath, 0.98; 95% CI, 0.84–1.15).
Strict (versus usual) BP control was protective against ESRD among those ≥40 years (HRESRD, 0.82; 95% CI, 0.71–0.94) but not
<40 years. Strict (versus usual) BP control was also protective against ESRD among those with body mass index ≥30 kg/m2
(HRESRD, 0.75; 95% CI, 0.61–0.92) but not body mass index <30 kg/m
2.
Conclusions-—The ESRD and all-cause mortality benefits of intensive BP lowering may not be uniform across all subgroups of
patients with chronic kidney disease. But intensive BP lowering was not associated with increased risk of ESRD or death among
any subgroups that we examined. ( J Am Heart Assoc. 2019;8:e012749. DOI: 10.1161/JAHA.119.012749.)
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T he 2017 American Heart Association guidelines recentlylowered the blood pressure (BP) level that defines
hypertension from 140/90 to 130/80 mm Hg for all patients
with chronic kidney disease (CKD).1 These guidelines were
strongly influenced by the results of the recent SPRINT
(Systolic Blood Pressure Intervention Trial), which demon-
strated lower cardiovascular morbidity and all-cause mortality
among patients with and without CKD at elevated cardiovas-
cular risk who were randomized to a lower systolic BP target
of <120 mm Hg.1–3 However, the results of SPRINT have
sparked considerable debate over optimal BP targets for
individuals with different risk factors.4–6
Despite the cardiovascular and mortality benefit seen with
intensive BP lowering, SPRINT did not demonstrate a benefit of
strict BP control on renal outcomes before the trial was
stopped early by the Data Safety and Monitoring Board. But
there were only a small number of kidney events in SPRINT.7
The results of SPRINT are consistent with those of other trials
in nondiabetic CKD, which also failed to demonstrate in their
primary analyses a benefit to intensive BP lowering over a
relatively short time period on renal or mortality outcomes.8–11
Post hoc analyses of SPRINT have suggested potential harm
with an intensive BP-lowering approach among patients with
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CKD, including a higher risk for acute kidney injury, although
most patients with CKD did recover from these acute kidney
injury episodes, and acute kidney injury was not a primary
outcome in SPRINT.2,12
Because the duration of most clinical trials of intensive BP
control have been short (mean duration, 3 years),8–11 trials
that are stopped early may have exaggerated effect sizes,13,14
and lower BP targets may be difficult to achieve in all patients
with CKD, there is a need for longer-term studies of the effect
of intensive BP control on CKD and mortality outcomes, which
may occur over many years. In particular, there is a paucity of
trial-based evidence to support appropriate BP targets among
patients with advanced CKD (stage 4 or beyond) and among
young patients with CKD (eg, 18–40 years of age) because of
their underrepresentation in most clinical trials. There have
also been few studies that have examined whether the effect
of intensive BP lowering is more pronounced among patients
who have other concurrent metabolic or cardiovascular risk
factors, such as obesity, a known risk factor for both CKD
progression and death.15–18 Furthermore, current guidelines
suggest that selection of BP targets be based on the
estimated atherosclerotic cardiovascular disease risk, but
the available risk estimators have not been validated and may
not be applicable to patients <40 years of age.1,19
The objective of this study was to explore the long-term
effects of intensive BP lowering on the risk of end-stage renal
disease (ESRD) or death among CKD subgroups of interest.
We were specifically interested in determining: (1) the
threshold of baseline proteinuria that associates with renal
or mortality benefit given prior post hoc analysis of trials that
have noted at least a renal benefit from intensive BP control
among patients with varying degrees of proteinuria20–23; (2)
whether intensive BP lowering has differential effects on the
risk of ESRD or death in those with advanced (glomerular
filtration rate [GFR] <30 mL/min per 1.73 m2) versus earlier
stages of CKD; and (3) whether intensive BP lowering has
differential effects in younger patients (<40 years of age) or
among obese patients (body mass index [BMI] ≥30 kg/m2). In
addition, we were also interested in whether the impact of
intensive BP lowering on mortality risk was primarily noted
during the CKD phase of illness versus after the onset of
ESRD (overall and by subgroups of interest). To enhance our
ability to perform subgroup analyses, we pooled participants
from 2 completed randomized controlled trials with long-term
follow-up for study: the AASK (African American Study of
Kidney Disease and Hypertension) and the MDRD (Modifica-
tion of Diet in Renal Disease) trial.8,10,20,24
Methods
Study Population
AASK was a large 293 factorial randomized controlled study
that assessed the effect of strict BP control and antihyper-
tensive agents on the progression of CKD in blacks (N=1094).
Details of the trial design and results have been pub-
lished.10,20,24 Between 1995 and 2001, participants between
18 and 70 years of age with measured GFR 20 to 65 mL/min
per 1.73 m2 were randomized to either strict (mean arterial
pressure [MAP] ≤92 mm Hg) versus usual (MAP 102–
107 mm Hg) BP control. Patients were also simultaneously
randomized to an angiotensin-converting enzyme inhibitor
(ramipril), sustained-release b blocker (metoprolol), or calcium
channel blocker (amlodipine) as their first-line antihyperten-
sive agent in 2:2:1 assignment, respectively. Patients with a
history of malignant hypertension, diabetes mellitus, causes
of renal disease other than hypertensive nephrosclerosis,
pregnancy, clinical evidence of heart failure, or proteinuria
≥2.5 g/d were excluded from study. At trial closure, 689
participants (of the original 1094) who had not developed
ESRD or died continued in the observational cohort study,
which began in April 2002 and ended June 30, 2007.23,25 All
AASK cohort participants were switched as first-line therapy
to an angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker if angiotensin-converting enzyme inhibitor
could not be tolerated with a target BP of <140/90 mm Hg,
which was modified in 2004 to <130/80 mm Hg as a result
of publication of the Joint National Committee 7
guidelines.23,26
The MDRD trial was a large 292 factorial design random-
ized controlled trial of the effect of strict BP control and
dietary protein restriction on the progression of CKD (N=840).
Details of the study design and results have been previously
published.8 Briefly, between 1989 and 1993, CKD patients
between 18 and 70 years of age with measured GFR 13 to
55 mL/min per 1.73 m2 were randomized to either strict or
usual BP control.8,27 Strict BP control was defined as a target
Clinical Perspective
What Is New?
• Intensive blood pressure lowering has variable effects on
the risk of end-stage renal disease and mortality, depending
on the presence or absence of baseline risk factors among
patients with chronic kidney disease.
What Are the Clinical Implications?
• Intensive blood pressure lowering appears to be especially
beneficial in reducing risk of end-stage renal disease among
patients who are older, are obese, or have more proteinuria.
• Intensive blood pressure lowering is also especially bene-
ficial in reducing the risk of death among those with
advanced chronic kidney disease.
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MAP ≤92 mm Hg (corresponds to 125/75 mm Hg) for
participants <61 years of age and a target MAP ≤98 mm Hg
(corresponds to 135/80 mm Hg) for participants ≥61 years
of age. Usual BP control was defined as a target MAP
≤107 mm Hg (corresponds to 140/90 mm Hg) for partici-
pants <61 years of age and a target MAP ≤113 mm Hg
(corresponds to 160/90 mm Hg) for participants ≥61 years
of age.8 Angiotensin-converting enzyme inhibitors with or
without diuretics were encouraged as first-line antihyperten-
sive agents. Patients with urine protein ≥10 g/d, diabetes
mellitus requiring insulin, class 3 or 4 heart failure, doubtful
compliance, pregnancy, or serum albumin <3 g/dL were
excluded. At trial closure, no specific BP targets were
recommended, and data on long-term BP control after trial
closure are not available.
The MDRD trial and AASK primary data have been made
publicly available at the National Institute of Diabetes and
Digestive and Kidney Diseases Central Repository and can be
accessed at https://repository.niddk.nih.gov/home/.28
Outcome
The primary outcomes of interest in our study were ESRD and
mortality. To extend ascertainment of ESRD and vital status
through 2012, we performed linkage of AASK and MDRD trial
participants with the US Renal Data System, the national
ESRD registry, and the national death indexes, as previously
described.29–32 Patients were censored as of June 30, 2012, if
they had not developed ESRD or died by this date. For this
study, to ensure uniform ascertainment, we defined ESRD as
receipt of chronic dialysis or kidney transplant, according to
the US Renal Data System database, over the entire study
duration. AASK patients without identifiers available for
linkage to external databases (N=27) were excluded from
analyses, leaving 1067 participants for inclusion in the
present study. No MDRD trial participants were excluded
from study. Institutional review board approval was obtained
for data linkage at the University of California, San Francisco,
and the Cleveland Clinic.
Statistical Analysis
We included 1067 AASK participants and 840 MDRD trial
participants for study, and we pooled both trials for analysis
to enhance generalizability and power among the subgroups
of interest after testing for and finding no interaction between
BP arm assignment and trial data source for both outcomes of
interest. We tested for differences between characteristics of
patients in subgroups of interest using t tests, Wilcoxon rank-
sum tests, and v2 tests.
To preserve the original randomization scheme, all
primary analyses were conducted in an intention-to-treat
manner using BP arm assignment as the primary predictor,
but all primary models allowed for different baseline hazards
for each trial in our Cox models. Risk factors of interest that
we thought could modify the effect of intensive BP control
on outcomes included level of GFR ≥30 or <30 mL/min per
1.73 m2 (according to Kidney Disease Improving Global
Outcomes guidelines for CKD staging),33 age (≥40 or
<40 years), and BMI (≥30 or <30 kg/m2): these cutoffs
were selected as clinically relevant thresholds for each
factor of interest. Thus, we first performed stratified analysis
by the risk factor of interest (eg, stage 4–5 CKD versus
stage 3 CKD) using unadjusted Cox models for the
outcomes of ESRD and death in separate models, pooling
data from both trials and allowing separate baseline hazards
for each trial. Both pre-ESRD and post-ESRD deaths were
included. In Cox models with ESRD as the outcome, deaths
occurring before ESRD were treated as a censoring event. In
sensitivity analysis, we treated death as a competing risk in
Fine-Gray models focused on ESRD. We considered unad-
justed models our primary analysis given that we were
testing the effect of the randomized intervention among
subgroups of interest.
In secondary analysis, we repeated these analyses,
adjusting for age, sex, race, measured GFR, BMI, and
proteinuria category, but still allowed separate baseline
hazards for each trial.
Next, we explored whether interactions were present
between randomized BP goal assignment and kidney function,
age, or BMI categories using our primary models for the risk
of ESRD and death using pooled trial data. Tests for
interaction were performed in separate models for each risk
factor of interest.
We also tested for the presence of interaction between
the logarithm of proteinuria (as a continuous variable) and
the BP target assignment. Once we found the presence of
an interaction, we determined the threshold of proteinuria at
which intensive BP lowering was associated with risk of
ESRD by using Cox models with 0.1g/g incremental
thresholds of proteinuria to find the exact magnitude of
proteinuria at which strict BP control became associated
with benefit for the outcome of ESRD (ie, such that there
was an interaction between BP arm assignment and
proteinuria categories; Table S1). We found a difference in
the risk of ESRD when proteinuria levels were <0.44 g/g.
We then performed unadjusted and adjusted Cox models
stratified by proteinuria categorized as ≥0.44 or <0.44 g/g
as described above, and explored whether an interaction
was present between BP arm assignment and proteinuria
category.
Finally, we examined whether there was a difference in the
effect of strict versus usual BP control on risk of death during
the pre-ESRD phase of illness versus after the onset of ESRD.
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We tested for interaction between BP arm assignment and
ESRD onset (as a time-dependent covariate) for the risk of
death.
We then examined the death rate during the CKD
compared with the ESRD phase of illness overall and by
subgroups of interest. Log-rank tests were used to determine
whether the rate of death differed by BP arm assignment
among all groups of interest.
All analyses were conducted using Stata 14 and verified by
separate analyst using SAS. Institutional Review Board
approval was obtained at University of California, San
Francisco, for data linkage and secondary data analysis.
Informed consent was obtained from all subjects for
participation in the MDRD trial and AASK and AASK cohort
studies.
Results
The baseline characteristics of MDRD trial and AASK
participants included in this study (N=1907) are shown in
Table 1. The mean age of participants was 53 years, median
proteinuria was 0.12 g/g, and median GFR was 40 mL/min
per 1.73 m2 (Table 1). The characteristics of participants
stratified by proteinuria, GFR, BMI, and age categories in the
intensive and usual BP treatment arms are shown in
Table 2.
Median follow-up starting from the time of randomization
until death or administrative censoring was 14.9 (interquartile
range, 9.6–15.8) years. There were 482 deaths and 526 ESRD
cases among those randomized to the usual BP control arm
and 438 deaths and 498 ESRD cases in the strict BP control
arm. We did not find the presence of any interaction between
BP arm assignment and trial data source (P>0.10) for the
outcomes of ESRD or death.
Overall, there was a statistically significant benefit from
strict versus usual BP control in unadjusted analysis for the
outcomes of death and ESRD (Figure A and B), as previously
described.29–31 Similar findings were noted in adjusted
analyses for the outcome of ESRD (Table S2).
For the outcome of death, in stratified analysis, the
unadjusted risk of death was lower among those assigned to
strict versus usual BP control if the participant had a baseline
GFR <30 mL/min per 1.73 m2 (hazard ratio [HR], 0.73; 95%
CI, 0.59–0.92; FigureA). In contrast, those with higher
baseline GFR had no statistically significant mortality benefit
from strict (versus usual) BP control (FigureA). Similarly, those
with more proteinuria at baseline tended to have lower risk of
death from intensive BP lowering (FigureA), although there
was not a statistically significant interaction (P>0.05). Results
from adjusted analyses are shown in Table S2. For the
outcome of death, we noted a statistically significant inter-
action between BP arm assignment and GFR category
(P=0.02). There appeared to be no statistically significant
difference in the risk of death by baseline proteinuria, BMI
category, or age category (Figure A).
For the outcome of ESRD, we found a protective effect of
strict (versus usual) BP control (HR, 0.77; 95% CI, 0.64–
0.92) among those with more proteinuria (FigureB). This was
not seen among participants with less baseline proteinuria
(HR, 0.95; 95% CI, 0.81–1.12), as would be expected given
that we searched for the threshold at which effect modifi-
cation was present by baseline proteinuria. There was a
statistically significant beneficial effect of strict (versus
usual) BP control among older participants (HR, 0.82; 95%
CI, 0.71–0.94) but not among younger participants (FigureB).
There was also a statistically significant beneficial effect of
strict (versus usual) BP control among obese (HR, 0.75; 95%
CI, 0.61–0.92) but not among nonobese participants
(FigureB). Results from adjusted analyses are shown in
Table S2. The effect of strict BP control appeared to differ
depending on age category (P=0.006 for interaction) and
BMI category (P=0.03 for test for interaction), but not
baseline GFR (P=0.87 for test for interaction) in unadjusted
analysis.
In sensitivity analysis, even after accounting for the
competing risk of death in Fine-Gray models, strict (versus
usual) BP control was associated with a lower risk of ESRD
among those with more proteinuria, older age, or obesity at
baseline (Table 3).
Finally, we examined the risk of death before versus after
the onset of ESRD. Death rates were 2- to 3-fold higher after
onset of ESRD than during the CKD phase of illness (Table 4).
Differences in death rates among those assigned to strict
versus usual BP control were more pronounced after ESRD
Table 1. Overall Characteristics of MDRD Trial and AASK
Participants at Baseline (N=1907)
Characteristic Value
Age, y 5311
Women 746 (39)
Black 1133 (59)
Baseline MAP, mm Hg 10716
Baseline proteinuria, g/d 0.12 (0.04–0.62)
Baseline GFR, mL/min per 1.73 m2 40 (28–52)
Baseline BMI, kg/m2 296
Assignment to strict BP control 954 (50)
Assignment to ACE inhibitor in AASK only 425/1067 (40)
Data are given as meanSD, number (percentage), or median (interquartile range). AASK
indicates African American Study of Kidney Disease and Hypertension; ACE, angiotensin-
converting enzyme; BMI, body mass index; BP, blood pressure; GFR, glomerular filtration
rate; MAP, mean arterial pressure; MDRD, Modification of Diet in Renal Disease.
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onset compared with during the CKD phase of illness
(Table 4).
Discussion
In this study, we pooled 2 completed trials of intensive BP
lowering to examine its effect on risk of ESRD or death on the
basis of baseline proteinuria, GFR, age, and BMI. For the
outcome of mortality, we found that intensive BP control was
especially beneficial among those with lower GFR at baseline.
For the outcome of ESRD, intensive BP lowering was especially
beneficial among those with more baseline proteinuria, older
age, and higher BMI. We identified that presence of ≥0.44 g/g
of proteinuria may help identify individuals who may especially
benefit from intensive BP lowering. We also found that intensive
BP lowering appeared to have particularly large benefits for the
risk of death after the onset of ESRD, as opposed to during the
CKD phase of illness. We believe our study is unique in its
Table 2. Baseline Characteristics by CKD Subgroups of Interest
Characteristic Usual BP Strict BP P Value Usual BP Strict BP P Value
Proteinuria, g/g <0.44 ≥0.44
Age, y 5511 5411 0.86 5012 5013 0.53
Women 254 (39) 271 (41) 0.45 126 (42) 95 (33) 0.02
Black 434 (66) 424 (64) 0.36 143 (48) 132 (46) 0.55
Baseline MAP, mm Hg 10715 10717 0.57 10715 10815 0.36
Baseline GFR, mL/min per 1.73 m2 46 (33–56) 45 (33–55) 0.29 28 (22–38) 31 (23–44) 0.03
Baseline proteinuria, g/d 0.06 (0.03–0.12) 0.06 (0.03–0.14) 0.54 1.19 (0.71–1.87) 1.11 (0.68–1.82) 0.78
BMI, kg/m2 28 (25–32) 28 (25–32) 0.39 28 (25–33) 28 (24–32) 0.72
GFR, mL/min per 1.73 m2 ≥30 <30
Age, y 5411 5411 0.42 5212 5013 0.03
Women 250 (38) 258 (37) 0.74 130 (44) 108 (41) 0.57
Black 463 (71) 475 (69) 0.42 114 (38) 81 (31) 0.07
Baseline MAP, mm Hg 10815 10916 0.22 104 14 103 15 0.51
Baseline GFR, mL/min per 1.73 m2 47 (39–56) 47 (38–55) 0.17 24 (20–27) 23 (19–27) 0.19
Baseline proteinuria, g/d 0.07 (0.03–0.29) 0.07 (0.03–0.36) 0.40 0.59 (0.12–1.44) 0.46 (0.13–1.41) 0.82
BMI, kg/m2 29 (25–33) 29 (25–33) 0.73 27 (24–31) 26 (23–30) 0.06
Age category, y <40 ≥40
Age, y 335 335 0.97 568 569 0.76
Women 57 (45) 47 (33) 0.053 323 (39) 319 (39) 0.96
Black 58 (46) 61 (43) 0.69 519 (63) 495 (61) 0.42
Baseline MAP, mm Hg 10517 10820 0.17 10715 10815 0.68
Baseline proteinuria, g/d 0.37 (0.09–1.21) 0.40 (0.1–1.29) 0.34 0.10 (0.03–0.54) 0.10 (0.03–0.49) 0.55
Baseline GFR, mL/min per 1.73 m2 37 (27–48) 32 (24–47) 0.12 40 (28–53) 42 (30–53) 0.29
BMI, kg/m2 26 (23–30) 27 (23–33) 0.20 28 (25–33) 28 (25–32) 0.26
BMI category, kg/m2 <30 ≥30
Age, y 5312 5312 0.93 5410 5311 0.51
Women 235 (39) 219 (37) 0.52 145 (42) 147 (41) 0.77
Black 315 (52) 291 (49) 0.33 262 (76) 265 (74) 0.51
Baseline MAP, mm Hg 10515 10616 0.91 11015 11217 0.14
Baseline proteinuria, g/d 0.11 (0.04–0.65) 0.11 (0.04–0.63) 0.64 0.12 (0.03–0.65) 0.14 (0.04–0.55) 0.58
Baseline GFR, mL/min per 1.73 m2 37 (26–50) 38 (26–50) 0.85 44 (31–55) 45 (34–54) 0.43
BMI, kg/m2 26 (24–28) 26 (23–28) 0.11 35 (32–38) 34 (32–38) 0.26
Data are given as column meanSD, number (percentage), or median (interquartile range). BMI indicates body mass index; BP, blood pressure; CKD, chronic kidney disease; GFR,
glomerular filtration rate; MAP, mean arterial pressure.
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AMDRD and AASK
N=1907
N Number of 
deaths
Usual BP
Death per 100 
person-years
Strict BP
Death per 100 
person-years
Unadjusted HR (95% CI)
Strict vs Usual
Overall 1907 920 3.7 3.3 0.87 (0.76-0.99)
Urine protein < 0.44 g/day 1319 591 3.3 3.1 0.93 (0.79-1.09)
Urine protein ≥ 0.44 g/day 588 329 4.7 3.7 0.77 (0.62-0.96)
GFR ≥ 30 mL/min/1.73 m2 343 592 3.2 3.1 0.98 (0.84-1.15)
GFR < 30 mL/min/1.73 m2 249 328 5.0 3.6 0.73 (0.59-0.92)
Age <40 years 268 53 1.1 1.2 1.02 (0.60-1.76)
Age ≥ 40 years 1639 867 4.3 3.7 0.86 (0.75-0.98)
BMI <30 kg/m2 1204 578 3.6 3.1 0.85 (0.72-1.00)
BMI ≥ 30 kg/m2 702 341 3.9 3.5 0.88 (0.71-1.09)
Hazard rao (95% CI)
0.4 0.6 0.8 1 1.2 1.4 1.6 1.8
Overall
Urine protein < 0.44 g/day (N=1319)
Urine protein ≥  0.44 g/day (N=588)
GFR ≥ 30 (N=1349)*
GFR <30 (N=558)*
Age <40 (N=268)
Age ≥40 (N=1639)
BMI <30 (N=1204)
BMI ≥ 30 (N=702)
Risk of Death in AASK and MDRD
*p<0.05 for interacon
B
MDRD and AASK
N=1907
N Number of ESRD 
events
Usual BP
ESRD per 100 
person-years
Strict BP
ESRD per 100 
person-years
Unadjusted HR (95% CI)
Strict vs Usual
Overall 1907 1024 6.0 5.4 0.88 (0.78-1.00)
Urine protein < 0.44 g/day 1319 569 4.0 4.0 0.95 (0.81-1.12)
Urine protein ≥ 0.44 g/day 588 455 14.1 10.8 0.77 (0.64-0.92)
GFR ≥ 30 mL/min/1.73 m2 1349 572 4.0 3.7 0.90 (0.77-1.06)
GFR < 30 mL/min/1.73 m2 558 452 14.6 14.4 0.95 (0.79-1.15)
Age <40 years 268 213 9.1 11.0 1.23 (0.94-1.61)
Age ≥ 40 years 1639 811 5.5 4.7 0.82 (0.71-0.94)
BMI <30 kg/m2 1204 665 6.0 5.9 0.96 (0.83-1.12)
BMI ≥ 30 kg/m2 702 358 6.0 4.7 0.75 (0.61-0.92)
0.4 0.6 0.8 1 1.2 1.4 1.6 1.8
Overall
Urine protein < 0.44 g/day (N=1319)*
Urine protein ≥  0.44 g/day (N=588)*
GFR ≥ 30 (N=1349)
GFR <30 (N=558)
Age <40 (N=268)*
Age ≥40 (N=1639)*
BMI <30 (N=1204)*
BMI ≥ 30 (N=702)*
Hazard Rao
Risk of ESRD in AASK and MDRD
*p<0.05 for interacon
Hazard rao (95% CI)
Figure. A, Unadjusted risk of death by blood pressure (BP) arm assignment comparing strict vs usual BP control.
B, Unadjusted risk of end-stage renal disease (ESRD) by BP arm assignment comparing strict vs usual BP control.
AASK indicates African American Study of Kidney Disease and Hypertension; BMI, body mass index; GFR,
glomerular filtration rate; HR, hazard ratio; MDRD, Modification of Diet in Renal Disease.
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provision of long-term follow-up that extends beyond the mean
duration of most clinical trials (2–3 years).
In contrast to large observational studies suggesting that
lower BP levels are associated with higher risk of mortality in
patients with CKD,34,35 we did not find evidence of harm in
any subgroups explored when this intervention was tested in a
randomized trial. We found the effect of intensive BP lowering
to be especially protective from a mortality standpoint among
those with advanced CKD at baseline enrollment. We believe
this finding may be related to the higher cardiovascular risk
among patients with advanced CKD and, therefore, greater
derived benefit from intensive BP lowering and its cardiovas-
cular benefits, although we are limited in the lack of data on
cardiovascular events posttrial closure.2 Intensive BP lowering
during the CKD phase of illness may also serve to improve the
cardiovascular health of patients once they transition to ESRD
and, thereby, lower the risk of death after onset of ESRD
(when cardiovascular mortality risk is at its peak).31 Our data
offer reassurance that intensive BP lowering did not appear to
be associated with harm in any of the subgroups we analyzed
in the trial settings and are overall consistent with the results
of SPRINT, although the MDRD trial and AASK enrolled a
population with greater severity of kidney disease and
proteinuria compared with SPRINT and targeted MAP as
opposed to systolic BP.
Although a few prior post hoc analyses of clinical trials
have suggested a renal benefit with an intensive BP-lowering
strategy among patients with significant proteinuria, most of
these studies have focused on change in the slope of kidney
function decline as an outcome and not ESRD onset.20,21,36
Recent studies have suggested that slopes of renal function
decline or albuminuria may not be associated with risk of
ESRD as strongly as would be needed for these outcomes to
serve as surrogate end points.37 In prior post hoc trial
analyses and meta-analyses, the level of proteinuria needed
for intensive BP lowering to be associated with renal benefit
varied considerably and ranged from a protein/creatinine
ratio of 0.22 to 1.5 g/g.21,23,36,38,39 In our study, we found
that proteinuria ≥0.44 g/g may serve as a threshold that
identifies patients who would benefit from intensive BP
control because of the presence of proteinuria.
We note that there was significant heterogeneity in the
effect of intensive BP lowering, depending on the character-
istics of patients at baseline enrollment into the MDRD trial
and AASK. Traditionally, most trials have not routinely
reported the heterogeneity in the effect of the intervention
being tested by baseline risk for outcomes of interest.40,41
A network meta-analysis of randomized trials recently
Table 3. Risk of ESRD Accounting for the Competing Risk of
Death
MDRD Trial and AASK (N=1907)
Unadjusted Sub-HR (95% CI)
Strict vs Usual
Overall 0.90 (0.80–1.02)
Urine protein <0.44 g/g* 0.99 (0.84–1.17)
Urine protein ≥0.44 g/g* 0.76 (0.63–0.91)
GFR ≥30 mL/min per 1.73 m2 0.94 (0.80–1.10)
GFR <30 mL/min per 1.73 m2 0.93 (0.77–1.12)
Age <40 y* 1.18 (0.90–1.54)
Age ≥40 y* 0.85 (0.74–0.98)
BMI <30 kg/m2 0.97 (0.83–1.13)
BMI ≥30 kg/m2 0.79 (0.65–0.98)
AASK indicates African American Study of Kidney Disease and Hypertension; BMI, body
mass index; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HR, hazard
ratio; MDRD, Modification of Diet in Renal Disease.
*P<0.05 for interaction.
Table 4. Death Rate Before and After ESRD by Subgroups of Interest
Variable
Death Rate (per 100-Person Years) During CKD
(95% CI)
Death Rate (per 100-Person Years) during ESRD
(95% CI)
Usual BP Strict BP Usual BP Strict BP
Overall 2.1 (1.8–2.4) 2.2 (1.9–2.5) 7.1 (6.4–8.0)* 5.6 (4.9–6.3)*
Urine protein <0.44 g/d 2.2 (1.9–2.6) 2.1 (1.8–2.5) 7.2 (6.1–8.4) 6.2 (5.2–7.3)
Urine protein ≥0.44 g/d 1.7 (1.2–2.5) 2.3 (1.7–3.1) 7.1 (6.0–8.3)* 4.9 (4.0–6.0)*
GFR ≥30 mL/min per 1.73 m2 2.2 (1.9–2.5) 2.2 (1.9–2.5) 6.9 (5.8–8.2) 6.8 (5.7–8.0)
GFR <30 mL/min per 1.73 m2 1.7 (1.2–2.5) 2.2 (1.6–3.1) 7.3 (6.3–8.5)* 4.5 (3.7–5.5)*
Age <40 y 0.5 (0.2–1.2) 0.8 (0.4–1.5) 1.8 (1.1–2.8) 1.4 (0.9–2.2)
Age ≥40 y 2.3 (2.0–2.7) 2.3 (2.0–2.7) 9.0 (8.0–10.2) 7.6 (6.6–8.7)
BMI <30 kg/m2 2.1 (1.7–2.5) 2.3 (1.9–2.7) 6.7 (5.8–7.7)* 4.6 (3.9–5.4)*
BMI ≥30 kg/m2 2.1 (1.7–2.7) 2.0 (1.6–2.6) 8.1 (6.7–9.8) 8.1 (6.6–9.9)
BMI indicates body mass index; BP, blood pressure; CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate.
*Statistically significantly different comparing strict vs usual BP arm assignment (P<0.05).
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demonstrated that, although intensive BP lowering was
effective in reducing the risk of cardiovascular outcomes,
the risk of serious adverse events was higher with lower BP
targets.42 Our study explores patient characteristics that
would favor intensification of BP control (eg, those with
advanced CKD for survival benefit and those who are older,
are obese, or have proteinuria for reduction in ESRD risk).
The strengths of our study include the large number of
ESRD events and deaths and the availability of nearly 2
decades of follow-up in AASK and MDRD trial participants. In
addition, we provide pooled data from 2 separate trials with a
racially diverse group of participants and are able to provide
data on the effect of an intervention delivered pre-ESRD on
outcomes after the onset of ESRD.
However, there are several limitations to our study. Our
results may not apply to people with CKD attributed to
diabetes mellitus. Although we had prespecified interest in
the subgroups divided by GFR, BMI, and age thresholds, we
recognize the potential for multiple hypothesis testing and
that not all risk factors were noted to be statistically
significant effect modifiers. We do not have detailed data
surrounding cardiovascular events (eg, stroke or new-onset
heart failure) that may have developed with each of the
treatment strategies during long-term follow-up. We acknowl-
edge that our study is post hoc and observational and that our
results may reflect the “legacy effect”43 of BP lowering during
these trials. Because of this, we believe that the findings in
our study likely underestimate the true potential impact of
intensive BP lowering, given the likely convergence of BP
levels between the strict and usual BP arms posttrial closure,
which would have attenuated the effects that we report and
were most of our follow-up period.
In recognition of the challenges of achieving adequate BP
control in the CKD population,44–46 targeting patients who
may have the greatest kidney and mortality benefits for the
achievement of aggressive BP lowering is important. We
suggest that patients with more proteinuria (>0.44 g/g) may
particularly benefit from achievement of lower BP targets.
Long-term benefits of intensive BP lowering after the transi-
tion from CKD to ESRD may also be a factor for consideration
when selecting BP treatment targets. Further studies are
needed to individualize the approach to BP target selection
and balance the risk of ESRD with that of mortality and other
adverse effects of treatment.
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SUPPLEMENTAL MATERIAL 
Table S1. Thresholds for statistically significant interaction between BP arm 
assignment and baseline proteinuria for the outcome of ESRD. 
 
MDRD and AASK 
N=1907 
P-value 
Urine protein < 0.3 g/g 
(versus ≥ 0.3 g/g)  
0.09 
Urine protein < 0.4 g/g  
(versus ≥ 0.4 g/g) 
0.07 
Urine protein < 0.43 g/g 
(versus ≥ 0.43 g/g) 
0.056 
Urine protein < 0.44 g/g 
(versus ≥ 0.44 g/g) 
0.044 
Urine protein < 0.45 g/g 
(versus ≥ 0.45 g/g) 
0.04 
Urine protein < 0.5 g/g 
(versus ≥ 0.5 g/g) 
0.02 
Urine protein < 0.6 g/g 
(versus ≥ 0.6 g/g) 
0.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Risk of ESRD or death in Cox models comparing strict versus usual BP arms (HR = hazard ratio). 
 
 
 Death ESRD  
MDRD and AASK 
N=1907 
N Unadjusted HR(95% 
CI) 
Adjusted* HR  
(95% CI) 
Unadjusted HR 
(95% CI) 
Adjusted* HR  
(95% CI) 
Overall  1907 0.87 (0.76-0.99) 0.85 (0.75-0.97) 0.88 (0.78-1.00) 0.88 (0.78-0.99) 
Urine protein < 0.44 g/day  1319 0.93 (0.79-1.09) 0.93 (0.79-1.09) 0.95 (0.81-1.12) 0.96 (0.81-1.13) 
Urine protein ≥ 0.44 g/day  588 0.77 (0.62-0.96) 0.77 (0.61-0.96) 0.77 (0.64-0.92) 0.79 (0.65-0.96) 
GFR ≥ 30 mL/min/1.73 m2 1349 0.98 (0.84-1.15) 0.90 (0.77-1.06) 0.90 (0.77-1.06) 0.88 (0.75-1.04) 
GFR < 30 mL/min/1.73 m2 558 0.73 (0.59-0.92) 0.82 (0.66-1.03) 0.95 (0.79-1.15) 0.92 (0.76-1.11) 
Age <40 years  268 1.02 (0.60-1.76) 0.88 (0.51-1.53) 1.23 (0.94-1.61) 1.00 (0.76-1.33) 
Age ≥ 40 years 1639 0.86 (0.75-0.98) 0.88 (0.77-1.01) 0.82 (0.71-0.94) 0.85 (0.74-0.98) 
BMI < 30 kg/m2 1204 0.85 (0.72-1.00) 0.86 (0.73-1.01) 0.96 (0.83-1.12) 0.98 (0.84-1.15) 
BMI ≥ 30 kg/m2 702 0.88 (0.71-1.09) 0.90 (0.73-1.11) 0.75 (0.61-0.92) 0.67 (0.54-0.82) 
 
*Adjusted for age, sex, race, proteinuria (≥ versus < 0.5 g/g), GFR (≥ 30 versus < 30 mL/min/1.73 m2), BMI, and stratified 
for trial data source.   
 
 
 
